SCHEMBL1505063

SCHEMBL1505063

C=CCc1cccc2ncc3ccccc3c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
GPR3 P46089 1/20 0.47
GABRA1 P14867 1/20 0.37
GABRB2 P47870 1/20 0.37
MAPT P10636 6/20 0.36
MEN1 O00255 5/20 0.36
KMT2A Q03164 5/20 0.36
PKM P14618 4/20 0.36
THRB P10828 1/20 0.36
NPSR1 Q6W5P4 3/20 0.34
HTT P42858 3/20 0.34
ALDH1A1 P00352 3/20 0.34
USP2 O75604 2/20 0.34
LMNA P02545 1/20 0.34
HIF1A Q16665 1/20 0.34
TP53 P04637 1/20 0.34
PDGFRB P09619 1/20 0.34
PDGFRA P16234 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27588351 0.83 KDM4E (0.52) KDM4EGPR3MAPTKMT2AHTT
SCHEMBL9935646 0.81 KDM4E (0.53) KDM4EGPR3MAPTMEN1KMT2A
SCHEMBL9935648 0.81 KDM4E (0.53) KDM4EGPR3KMT2AHTTALDH1A1
SCHEMBL5801178 0.80 KDM4E (0.52) KDM4EGPR3MAPTMEN1KMT2A
SCHEMBL28355479 0.80 KDM4E (0.52) KDM4EGPR3MAPTMEN1KMT2A
SCHEMBL27279082 0.80 KDM4E (0.52) KDM4EGPR3KMT2AHTTALDH1A1
SCHEMBL27670163 0.79 CYP3A4 (0.45) KDM4EMAPTALDH1A1LMNAHIF1A
SCHEMBL16487070 0.77 ALDH1A1 (0.43) KDM4EGABRA1GABRB2MAPTMEN1
SCHEMBL1860385 0.77 KDM4E (0.49) KDM4EGPR3MAPTMEN1KMT2A
SCHEMBL4033783 0.77 KDM4E (0.49) KDM4EGPR3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103936661-B A kind of synthetic method of 6-alkyl phenanthrene piperidine derivatives 常州大学 2016-08-24 CN claimed
CN-115724797-A Fluoroalkylated 3, 4-polysubstituted dihydroisoquinoline skeleton novel compound and preparation method thereof 兰州大学 2023-03-03 CN disclosed
CN-108299297-A A kind of novel 6- alkyl phenanthridines and derivative and preparation method thereof 西京学院 2018-07-20 CN disclosed
CN-103936661-B A kind of synthetic method of 6-alkyl phenanthrene piperidine derivatives 常州大学 2016-08-24 CN disclosed
US-20120313089-A1 ORGANIC ELECTROLUMINESCENCE DEVICE UDC IRELAND LTD. (IE) 2012-12-13 US disclosed
US-8253130-B2 Organic electroluminescence device FUJIFILM CORPORATION (JP) 2012-08-28 US disclosed
US-20110073848-A1 ORGANIC ELECTROLUMINESCENCE DEVICE FUJIFILM CORPORATION (JP) 2011-03-31 US disclosed
US-20100291689-A1 Lanthanide Complexes as Fluorescent Indicators for Neutral Sugars and Cancer Diagnosis BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL AND MECHANICAL COLLEGE (US) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110073848-A1 ORGANIC ELECTROLUMINESCENCE DEVICE L1CAM, CYBA, EPCAM KDM4E 2517/4885GPR3 3296/4885GABRA1 2660/4885
US-20100291689-A1 Lanthanide Complexes as Fluorescent Indicators for Neutral Sugars and Cancer Diagnosis LPAR3, LPCAT1, LYPLAL1 KDM4E 3462/4885GPR3 420/4885GABRA1 4168/4885
US-20120313089-A1 ORGANIC ELECTROLUMINESCENCE DEVICE L1CAM, CYBA, EPCAM KDM4E 2517/4885GPR3 3296/4885GABRA1 2660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.